[HTML][HTML] Inflammatory cytokines and chemokines as therapeutic targets in heart failure
A Hanna, NG Frangogiannis - Cardiovascular Drugs and Therapy, 2020 - Springer
Heart failure exhibits remarkable pathophysiologic heterogeneity. A large body of evidence
suggests that regardless of the underlying etiology, heart failure is associated with induction …
suggests that regardless of the underlying etiology, heart failure is associated with induction …
Cardiac fibroblast: the renaissance cell
CA Souders, SLK Bowers, TA Baudino - Circulation research, 2009 - Am Heart Assoc
The permanent cellular constituents of the heart include cardiac fibroblasts, myocytes,
endothelial cells, and vascular smooth muscle cells. Previous studies have demonstrated …
endothelial cells, and vascular smooth muscle cells. Previous studies have demonstrated …
gp130 controls cardiomyocyte proliferation and heart regeneration
Y Li, J Feng, S Song, H Li, H Yang, B Zhou, Y Li… - Circulation, 2020 - Am Heart Assoc
Background: A key cause of the high mortality of cardiovascular diseases is the
cardiomyocyte inability to renew after cardiac injury. As a promising strategy to supplement …
cardiomyocyte inability to renew after cardiac injury. As a promising strategy to supplement …
Multiple facets of NF-κB in the heart: to be or not to NF-κB
JW Gordon, JA Shaw, LA Kirshenbaum - Circulation research, 2011 - Am Heart Assoc
The progression from cardiac injury to symptomatic heart failure has been intensely studied
over the last decade, and is largely attributable to a loss of functional cardiac myocytes …
over the last decade, and is largely attributable to a loss of functional cardiac myocytes …
Cardiac hypertrophy: the good, the bad, and the ugly
N Frey, EN Olson - Annual review of physiology, 2003 - annualreviews.org
▪ Abstract Cardiac hypertrophy is the heart's response to a variety of extrinsic and intrinsic
stimuli that impose increased biomechanical stress. While hypertrophy can eventually …
stimuli that impose increased biomechanical stress. While hypertrophy can eventually …
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia
A Bonetto, T Aydogdu, X Jin, Z Zhang… - American Journal …, 2012 - journals.physiology.org
Cachexia, the metabolic dysregulation leading to sustained loss of muscle and adipose
tissue, is a devastating complication of cancer and other chronic diseases. Interleukin-6 and …
tissue, is a devastating complication of cancer and other chronic diseases. Interleukin-6 and …
Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction
L Zhao, G Cheng, R Jin, MR Afzal, A Samanta… - Circulation …, 2016 - Am Heart Assoc
Rationale: The role of interleukin (IL)-6 in the pathogenesis of cardiac myocyte hypertrophy
remains controversial. Objective: To conclusively determine whether IL-6 signaling is …
remains controversial. Objective: To conclusively determine whether IL-6 signaling is …
An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy
Heart failure is a highly morbid and mortal clinical condition that represents the last stage of
most cardiovascular disorders. Diabetes is strongly associated with an increased incidence …
most cardiovascular disorders. Diabetes is strongly associated with an increased incidence …
Cytoplasmic signaling pathways that regulate cardiac hypertrophy
JD Molkentin, GW Dorn II - Annual review of physiology, 2001 - annualreviews.org
▪ Abstract This review discusses the rapidly progressing field of cardiomyocyte signal
transduction and the regulation of the hypertrophic response. When stimulated by a wide …
transduction and the regulation of the hypertrophic response. When stimulated by a wide …
Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?
S Lecour - Journal of molecular and cellular cardiology, 2009 - Elsevier
Lethal reperfusion injury is now recognized as a major limitation of current reperfusion
therapy by primary percutaneous coronary intervention for acute myocardial infarction …
therapy by primary percutaneous coronary intervention for acute myocardial infarction …